--- a
+++ b/clusters/9knumclustersv2/clust_1152.txt
@@ -0,0 +1,52 @@
+Patients must have measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within  days PRIOR TO STUDY ENTRY
+Subject has progressive disease with at least one measureable lesion on MRI.
+Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v.
+Measureable disease as defined by the RECIST ..
+Measureable disease (defined as at least . cm in diameter).
+Measureable disease per response evaluation criteria (RECIST) v.
+For Part G, H, and I: Have measureable disease as defined by RECIST ..
+Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST . criteria
+Has measureable disease by RECIST . criteria as assessed by the local site investigator/radiology.
+Measureable or evaluable disease by RECIST v. for solid tumors prior to the administration of study drug
+Must have measureable disease as per RECIST Version . or RANO (for GBM).
+Measureable disease according to RECIST Version .
+At least one measureable lesion as defined by RECIST version . that has not been previously irradiated
+Measureable disease
+Have measureable disease
+At least one measureable tumor lesion that that has not been previously locally
+Part  only: have measureable disease by RECIST
+Measureable disease.
+Measurable and/or non-measureable disease by RECIST criteria must be present
+Patients with measureable or non-measureable disease are eligible
+Measureable disease according to RECIST Version .
+Radiographically measureable disease.
+Has measureable disease
+Has measureable or nonmeasurable disease as defined by RECIST . criteria.
+Subjects must have measureable disease according to RECIST (version .).
+Radiographically measureable disease
+Radiographically measureable disease
+Radiographically measureable disease
+Measureable (target) disease.
+At least one measureable lesion by RECIST ..
+Have measureable disease per RECIST ..
+Subjects must have measureable disease as defined by RECIST . criteria or modified RECIST criteria
+Subjects who have brain metastasis as the only measureable lesion
+At least one measureable lesion as defined by RECIST version . that has not been previously irradiated.
+At least one measureable lesion.
+Measureable disease
+Measureable disease
+Chemoembolization is allowed if >=  weeks from study entry; there are  possible scenarios:\r\n* If patient has hepatic disease only: they need to have progressed in the liver since chemoembolization and have measureable disease by RECIST . in order to be eligible\r\n* If patient has hepatic and extrahepatic disease: they will need to have progressed inside OR outside the liver and have measureable disease by RECIST . in order to be eligible
+Measureable disease according to RECIST Version .
+Presence of measureable disease based on RECIST v.
+Subjects must have at least  lesion that is measureable using RECIST guidelines
+Measureable disease per RECIST v. prior to administration of study medication
+Patients must have measureable or evaluable disease
+Objective, measureable, symptomatic organ involvement, defined as one or more of the following:
+Measureable disease as per RECIST
+Presence of at least one measureable tumor lesion is required
+Women with >=  cm clinically or radiologically measureable breast cancer
+Previously untreated participants must have a measureable lesion on an imaging study
+Subject must have measureable disease by RECIST ..
+Presence of measureable disease based on RECIST v..
+Measureable disease
+Presence of measureable disease based on RECIST v.